Kobiolabs develops microbiome-based therapeutics using its Smartiome® platform, which employs AI-driven multi-omics analysis to create targeted treatments for immune, metabolic, and neurological disorders. By harnessing the complex interactions of the human microbiome, the company aims to address various health conditions linked to microbial imbalances.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many immune, metabolic, and neurological disorders are linked to imbalances in the human microbiome, but developing targeted treatments is challenging due to the complexity of microbial interactions. Traditional drug development approaches struggle to effectively harness the potential of the microbiome for therapeutic intervention.
Solution
Kobiolabs is developing microbiome-based therapeutics by leveraging its Smartiome® platform, which uses AI-driven multi-omics analysis to identify and develop targeted treatments. The platform analyzes the complex interactions within the human microbiome to address various health conditions associated with microbial imbalances. By focusing on immune, metabolic, and neurological disorders, Kobiolabs aims to create innovative therapies that modulate the microbiome for improved patient outcomes. The company utilizes a reverse-translational approach, "Human Data to Human Drug," to accelerate the drug discovery process.
Target Audience
The primary target audience includes patients suffering from immune, metabolic, and neurological disorders, as well as pharmaceutical companies seeking innovative microbiome-based therapeutics.
Features
- Smartiome® platform: An AI-driven platform for multi-omics analysis of the microbiome.
- Microbial library: A collection of diverse microbial strains for therapeutic development.
- Biofoundry: Utilized for Microbe-Based Drug Delivery System (mDDS) applications.
- Focus on immune, metabolic, and neurological disorders.